HIV-1 envelope glycoproteins isolated from Viremic Non-Progressor individuals are fully functional and cytopathic

Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals

BACKGROUND Progression rates from initial HIV-1 infection to advanced AIDS vary significantly among infected individuals. A distinct subgroup of HIV-1-infected individuals-termed viremic non-progressors (VNP) or controllers-do not seem to progress to AIDS, maintaining high CD4+ T cell counts despite high levels of viremia for many years. Several studies have evaluated multiple host factors, inc...

Structure of trimeric HIV-1 envelope glycoproteins.

A38 Diversity analyses of HIV-1 envelope glycoproteins in HIV-infected individuals with and without broadly neutralizing antibodies

A37 HIV drug resistance monitoring in children receiving first line antiretroviral therapy at two pediatric hospitals in Ho Chi Minh City Anh Q. Luong, Ton Tran, Khanh Thu H. Hoang, Ngoc Thao T. Do, Thinh X. Vu, Khanh H. Truong, Quy T. Du, Kim Thoa P. Le, Viet C. Do, An T. Vu, Thanh Thuy T. Le, Kim Chi T. Nguyen, Binh K. Nguyen, Hien. T Bui, Xuan Lien T. Truong, Pasteur Institute, Ho Chi Minh C...

Finding trimeric HIV-1 envelope glycoproteins in random noise.

In two recent papers, Mao et al. (1, 2) present the trimeric structure of the HIV-1 gp160 trimer at 11and 6-Å resolutions, respectively. The authors repeatedly emphasize their “reference-free,” “gold standard” methodology, but in neither of their papers do they state how the particles were selected from the electron micrographs. They do state (figure S3 in ref. 1): “Each row shows a sequence of...

HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees

Induction of broadly cross-reactive antiviral humoral responses with the capacity to target globally diverse circulating strains is a key goal for HIV-1 immunogen design. A major gap in the field is the identification of diverse HIV-1 envelope antigens to evaluate vaccine regimens for binding antibody breadth. In this study, we define unique antigen panels to map HIV-1 vaccine-elicited antibody...